Cotinine reduces depressive-like behavior, working memory deficits, and synaptic loss associated with chronic stress in mice

Behavioural Brain Research

Volumn 268, Issue , 2014, Pages 55-65

  Grizzell, J Alex ^a,b   Iarkov, Alexandre ^a   Holmes, Rosalee ^a   Mori, Takahashi ^c   Echeverria, Valentina ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

Cotinine; Depression; Memory; Restraint; Stress; Synaptophysin

Indexed keywords

ANTIDEPRESSANT AGENT; COTININE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NOOTROPIC AGENT; SYNAPTOPHYSIN; SYP PROTEIN, MOUSE;

ANIMAL; BRAIN; C57BL MOUSE; CHRONIC DISEASE; DEPRESSION; DISEASE MODEL; DRUG EFFECTS; DRUG THERAPY; EXERCISE; MALE; MEMORY DISORDERS; MENTAL STRESS; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SHORT TERM MEMORY; SYNAPSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CHRONIC DISEASE; COTININE; DEPRESSION; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICE, INBRED C57BL; MOTOR ACTIVITY; NOOTROPIC AGENTS; RESTRAINT, PHYSICAL; STRESS, PSYCHOLOGICAL; SYNAPSES; SYNAPTOPHYSIN;

EID: 84898884197     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.03.047     Document Type: Article

References (93)

1. Ehlert U., Gaab J., Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol Psychol 2001, 57:141-152.
2. Heim C., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Ann N Y Acad Sci 1997, 821:194-207.
3. Bremner J.D. Alterations in brain structure and function associated with post-traumatic stress disorder. Seminars Clin Neuropsychiat 1999, 4:249-255.
4. Wang Z., Neylan T.C., Mueller S.G., Lenoci M., Truran D., Marmar C.R., et al. Magnetic resonance imaging of hippocampal subfields in posttraumatic stress disorder. Arch Gen Psychiatry 2010, 67:296-303.
5. Ahmed F., Ras J., Seedat S. Volumetric structural magnetic resonance imaging findings in pediatric posttraumatic stress disorder and obsessive compulsive disorder: a systematic review. Front Psychol 2012, 3:568.
6. Stevens J.S., Jovanovic T., Fani N., Ely T.D., Glover E.M., Bradley B., et al. Disrupted amygdala-prefrontal functional connectivity in civilian women with posttraumatic stress disorder. J Psychiatr Res 2013, 47(10):1469-1478.
7. Weber M., Killgore W.D., Rosso I.M., Britton J.C., Schwab Z.J., Weiner M.R., et al. Voxel-based morphometric gray matter correlates of posttraumatic stress disorder. J Anxiety Disord 2013, 27:413-419.
8. Yehuda R., Giller E.L., Southwick S.M., Lowy M.T., Mason J.W. Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder. Biol Psychiatry 1991, 30:1031-1048.
9. Shalev A.Y., Videlock E.J., Peleg T., Segman R., Pitman R.K., Yehuda R. Stress hormones and post-traumatic stress disorder in civilian trauma victims: a longitudinal study. Part I: HPA axis responses. Int J Neuropsychopharmacol 2008, 11:365-372.
10. Morris M.C., Compas B.E., Garber J. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin Psychol Rev 2012, 32:301-315.
11. Buynitsky T., Mostofsky D.I. Restraint stress in biobehavioral research: recent developments. Neurosci Biobehav Rev 2009, 33:1089-1098.
12. McEwen B.S., Albeck D., Cameron H., Chao H.M., Gould E., Hastings N., et al. Stress and the brain: a paradoxical role for adrenal steroids. Vitam Horm 1995, 51:371-402.
13. Sapolsky R.M., Krey L.C., McEwen B.S. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci 1985, 5:1222-1227.
14. Watanabe Y., Gould E., McEwen B.S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res 1992, 588:341-345.
15. Donohue H.S., Gabbott P.L., Davies H.A., Rodriguez J.J., Cordero M.I., Sandi C., et al. Chronic restraint stress induces changes in synapse morphology in stratum lacunosum-moleculare CA1 rat hippocampus: a stereological and three-dimensional ultrastructural study. Neuroscience 2006, 140:597-606.
16. Pawlak R., Rao B.S., Melchor J.P., Chattarji S., McEwen B., Strickland S. Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci U S A 2005, 102:18201-18206.
17. Workman J.L., Manny N., Walton J.C., Nelson R.J. Short day lengths alter stress and depressive-like responses, and hippocampal morphology in Siberian hamsters. Hormones Behav 2011, 60:520-528.
18. Lambert K.G., Buckelew S.K., Staffiso-Sandoz G., Gaffga S., Carpenter W., Fisher J., et al. Activity-stress induces atrophy of apical dendrites of hippocampal pyramidal neurons in male rats. Physiol Behav 1998, 65:43-49.
19. Sousa N., Lukoyanov N.V., Madeira M.D., Almeida O.F., Paula-Barbosa M.M. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience 2000, 97:253-266.
20. Pham K., Nacher J., Hof P.R., McEwen B.S. Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. Eur J Neurosci 2003, 17:879-886.
21. Goldwater D.S., Pavlides C., Hunter R.G., Bloss E.B., Hof P.R., McEwen B.S., et al. Structural and functional alterations to rat medial prefrontal cortex following chronic restraint stress and recovery. Neuroscience 2009, 164:798-808.
22. Shansky R.M., Hamo C., Hof P.R., McEwen B.S., Morrison J.H. Stress-induced dendritic remodeling in the prefrontal cortex is circuit specific. Cereb Cortex 2009, 19:2479-2484.
23. Lee Y.A., Poirier P., Otani S., Goto Y. Dorsal-ventral distinction of chronic stress-induced electrophysiological alterations in the rat medial prefrontal cortex. Neuroscience 2011, 183:108-120.
24. Fuster J. The prefrontal cortex 2008, Academic Press, New York. 4th ed.
25. Kesner R.P., Martinez J.L. Neurobiology of learning and memory 2007, Academic Press, San Diego, CA. 2nd ed.
26. Shansky R.M., Rubinow K., Brennan A., Arnsten A.F. The effects of sex and hormonal status on restraint-stress-induced working memory impairment. Behav Brain Funct 2006, 2:8.
27. Abidin I., Yargicoglu P., Agar A., Gumuslu S., Aydin S., Ozturk O., et al. The effect of chronic restraint stress on spatial learning and memory: relation to oxidant stress. Int J Neurosci 2004, 114:683-699.
28. Naert G., Ixart G., Maurice T., Tapia-Arancibia L., Givalois L. Brain-derived neurotrophic factor and hypothalamic-pituitary-adrenal axis adaptation processes in a depressive-like state induced by chronic restraint stress. Mol Cell Neurosci 2011, 46:55-66.
29. Bremner J.D. Functional neuroimaging in post-traumatic stress disorder. Expert Rev Neurother 2007, 7:393-405.
30. Charney D.D. Neurobiology of mental illness 2011, Oxford University Press, New York, NY.
31. Vainio P.J., Tuominen R.K. Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes. Nicotine Tob Res 2001, 3:177-182.
32. Buccafusco J.J., Beach J.W., Terry A.V. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 2009, 328:364-370.
33. Cotinine Moran V.E. Beyond that expected, more than a biomarker of tobacco consumption. Front Pharmacol 2012, 3:173.
34. O'Leary K., Parameswaran N., McIntosh J.M., Quik M. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. J Pharmacol Exp Ther 2008, 325:646-654.
35. Riah O., Dousset J.C., Courriere P., Stigliani J.L., Baziard-Mouysset G., Belahsen Y. Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity. Toxicol Lett 1999, 109:21-29.
36. Goldberg S.R., Risner M.E., Stolerman I.P., Reavill C., Garcha H.S. Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology (Berlin) 1989, 97:295-302.
37. Riah O., Dousset J.C., Bofill-Cardona E., Courriere P. Isolation and microsequencing of a novel cotinine receptor. Cell Mol Neurobiol 2000, 20:653-664.
38. Keenan R.M., Hatsukami D.K., Pentel P.R., Thompson T.N., Grillo M.A. Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin Pharmacol Ther 1994, 55:581-590.
39. Zeitlin R., Patel S., Solomon R., Tran J., Weeber E.J., Echeverria V. Cotinine enhances the extinction of contextual fear memory and reduces anxiety after fear conditioning. Behav Brain Res 2012, 228:284-293.
40. Aguiar R.B., Parfitt G.M., Jaboinski J., Barros D.M. Neuroactive effects of cotinine on the hippocampus: behavioral and biochemical parameters. Neuropharmacology 2013, 71:292-298.
41. Terry A.V., Hernandez C.M., Hohnadel E.J., Bouchard K.P., Buccafusco J.J. Cotinine a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev 2005, 11:229-252.
42. Buccafusco J.J., Terry A.V. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 2009, 78:852-862.
43. Echeverria V., Zeitlin R., Burgess S., Patel S., Barman A., Thakur G., et al. Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice. J Alzheimers Dis 2011, 24:817-835.
44. Terry A.V., Buccafusco J.J., Schade R.F., Vandenhuerk L., Callahan P.M., Beck W.D., et al. The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem Pharmacol 2012, 83:941-951.
45. Echeverria V., Zeitlin R., Patel S., Solomon R., Tran J., Grizzell J.A., et al. Posttreatment with cotinine improved working memory, Reduced amyloid-beta plaques and decreased depressive-like behavior in the Tg6799 mice 2012, Society for Neuroscience, New Orleans, LA, USA.
46. Crooks P.A., Dwoskin L.P. Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 1997, 54:743-753.
47. Hatsukami D.K., Grillo M., Pentel P.R., Oncken C., Bliss R. Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol Biochem Behav 1997, 57:643-650.
48. Echeverria V., Zeitlin R. Cotinine: a potential new therapeutic agent against Alzheimer's disease. CNS Neurosci Therapeut 2012, 18:517-523.
49. Buccafusco J.J., Terry A.V. The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci 2003, 72:2931-2942.
50. De Schepper P.J., Van Hecken A., Daenens P., Van Rossum J.M. Kinetics of cotinine after oral and intravenous administration to man. Eur J Clin Pharmacol 1987, 31:583-588.
51. Benowitz N.L., Jacob P., Fong I., Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 1994, 268:296-303.
52. Riah O., Courriere P., Dousset J.C., Todeschi N., Labat C. Nicotine is more efficient than cotinine at passing the blood-brain barrier in rats. Cell Mol Neurobiol 1998, 18:311-318.
53. Lockman P.R., McAfee G., Geldenhuys W.J., Van der Schyf C.J., Abbruscato T.J., Allen D.D. Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J Pharmacol Exp Ther 2005, 314:636-642.
54. Takuma K., Mizoguchi H., Funatsu Y., Hoshina Y., Himeno Y., Fukuzaki E., et al. Combination of chronic stress and ovariectomy causes conditioned fear memory deficits and hippocampal cholinergic neuronal loss in mice. Neuroscience 2012, 207:261-273.
55. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
56. Arendash G.W., Mori T., Cao C., Mamcarz M., Runfeldt M., Dickson A., et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis 2009, 17:661-680.
57. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005, 29:571-625.
58. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
59. Castagne V., Moser P., Roux S., Porsolt R.D. Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci 2001, Chapter 8(Unit 8):10A. [editorial board, Jacqueline N Crawley et al. 2011].
60. Mori T., Koyama N., Arendash G.W., Horikoshi-Sakuraba Y., Tan J., Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 2010, 58:300-314.
61. Mori T., Rezai-Zadeh K., Koyama N., Arendash G.W., Yamaguchi H., Kakuda N., et al. Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 2012, 287:6912-6927.
62. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego, CA.
63. Beaulieu J.M., Gainetdinov R.R., Caron M.G. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 2009, 49:327-347.
64. King M.K., Pardo M., Cheng Y., Downey K., Jope R.S., Beurel E. Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol Ther 2013.
65. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 2006, 7:1421-1434.
66. Jope R.S. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 2011, 4:16.
67. Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Rev Psychiatr 1997, 4:231-244.
68. Dill J., Wang H., Zhou F., Li S. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci 2008, 28:8914-8928.
69. King M.K., Pardo M., Cheng Y., Downey K., Jope R.S., Beurel E. Glycogen synthase kinase-3 inhibitors: rescuers of cognitive impairments. Pharmacol Ther 2014, 141:1-12.
70. Gronli J., Murison R., Fiske E., Bjorvatn B., Sorensen E., Portas C.M., et al. Effects of chronic mild stress on sexual behavior, locomotor activity and consumption of sucrose and saccharine solutions. Physiol Behav 2005, 84:571-577.
71. Mihailescu S., Drucker-Coliin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res 2000, 31:131-144.
72. Fernandez J.W., Grizzell J.A., Wecker L. The role of estrogen receptor beta and nicotinic cholinergic receptors in postpartum depression. Prog Neuropsychopharmacol Biol Psychiatry 2013, 40:199-206.
73. Ziedonis D., Hitsman B., Beckham J.C., Zvolensky M., Adler L.E., Audrain-McGovern J., et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tobacco Res: Off J Soc Res Nicotine Tobacco 2008, 10:1691-1715.
74. Zabala A., Eguiluz J.I., Segarra R., Enjuto S., Ezcurra J., Gonzalez Pinto A., et al. Cognitive performance and cigarette smoking in first-episode psychosis. Eur Arch Psychiat Clin Neurosci 2009, 259:65-71.
75. Caldirola D., Dacco S., Grassi M., Citterio A., Menotti R., Cavedini P., et al. Effects of cigarette smoking on neuropsychological performance in mood disorders: a comparison between smoking and nonsmoking inpatients. J Clin Psychiatry 2013, 74:e130-e136.
76. Risner M.E., Goldberg S.R., Prada J.A., Cone E.J. Effects of nicotine, cocaine and some of their metabolites on schedule-controlled responding by beagle dogs and squirrel monkeys. J Pharmacol Exp Ther 1985, 234:113-119.
77. McEwen B.S. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci 2001, 933:265-277.
78. Wainwright S.R., Galea L.A. The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. Neural Plast 2013, 2013:805497.
79. Gamaro G.D., Michalowski M.B., Catelli D.H., Xavier M.H., Dalmaz C. Effect of repeated restraint stress on memory in different tasks. Braz J Med Biol Res 1999, 32:341-347.
80. Valtorta F., Pennuto M., Bonanomi D., Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis. Bioessays 2004, 26:445-453.
81. Zoladz P.R., Park C.R., Halonen J.D., Salim S., Alzoubi K.H., Srivareerat M., et al. Differential expression of molecular markers of synaptic plasticity in the hippocampus, prefrontal cortex, and amygdala in response to spatial learning, predator exposure, and stress-induced amnesia. Hippocampus 2012, 22:577-589.
82. Magarinos A.M., Deslandes A., McEwen B.S. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999, 371:113-122.
83. Franklin A.V., King M.K., Palomo V., Martinez A., McMahon L.L., Jope R.S. Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol Psychiatry 2014, 75:198-206.
84. Rehani K., Scott D.A., Renaud D., Hamza H., Williams L.R., Wang H., et al. Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim Biophys Acta 2008, 1783:375-382.
85. Bagaitkar J., Zeller I., Renaud D.E., Scott D.A. Cotinine inhibits the pro-inflammatory response initiated by multiple cell surface Toll-like receptors in monocytic THP cells. Tobacco Induced Dis 2012, 10:18.
86. Fuxe K., Everitt B.J., Hokfelt T. On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol Biochem Behav 1979, 10:671-677.
87. Dwoskin L.P., Teng L., Buxton S.T., Crooks P.A. (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J Pharmacol Exp Ther 1999, 288:905-911.
88. Beaulieu J.M. A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 2012, 37:7-16.
89. Chen L., Zhou W., Chen P.C., Gaisina I., Yang S., Li X. Glycogen synthase kinase-3beta is a functional modulator of serotonin-1B receptors. Mol Pharmacol 2011, 79:974-986.
90. Zhou W., Chen L., Paul J., Yang S., Li F., Sampson K., et al. The effects of glycogen synthase kinase-3beta in serotonin neurons. PLoS ONE 2012, 7:e43262.
91. Balakumar P., Kaur J. Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders. Pharmacol Res 2009, 60:361-368.
92. Karaconji I.B. Facts about nicotine toxicity. Arh Hig Rada Toksikol 2005, 56:363-371.
93. Hatsukami D., Pentel P.R., Jensen J., Nelson D., Allen S.S., Goldman A., et al. Cotinine: effects with and without nicotine. Psychopharmacology (Berlin) 1998, 135:141-150.